Evaluation of cost savings to a state medicaid program following a sertraline tablet-splitting program

Phillip J. Vuchetich, Robert I. Garis, Allison M.D. Jorgensen

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Objectives: To evaluate the economic impact of implementing a sertraline (Zoloft-Pfizer) tablet-splitting program on the Nebraska Medicaid program based on the change in total and per-member-per-month (PMPM) prescription drug costs and to identify any real or perceived problems with tablet splitting using switches among selective serotonin reuptake inhibitors (SSRIs) as a proxy indicator. Design: Retrospective study of prescription claims before and after the tablet-splitting program was implemented. Setting: Nebraska Medicaid. Patients: All 14,520 patients who received an SSRI during the study period, including 5,466 patients who received at least one prescription for sertraline. Interventions: The Nebraska Medicaid program implemented a mandatory tablet-splitting program for sertraline. Pharmacists were paid a supplemental fee to split tablets. Main Outcome Measures: Total costs, PMPM costs, and switches among SSRIs. Results: Using regression analysis, sertraline was the only SSRI that showed a downward slope in total cost per month, although the decrease was not statistically significant (P = .1156). Fluoxetine (Prozac - Eli Lilly) and paroxetine (Paxil - GlaxoSmithKline) both showed an upward slope, but the increases were not statistically significant (P = .1164 and .0671, respectively). Citalopram (Celexa-Forest) and fluvoxamine showed significantly positive upward slopes (P = .0001 and .0391, respectively). Sertraline was also the only SSRI that showed a downward slope in PMPM costs (P = .0093). Citalopram, fluvoxamine, fluoxetine, and paroxetine all showed an upward slope in PMPM costs (P = .4494, .0008, .0448, and .0482, respectively). The tablet-splitting program was not associated with a net change in patients being switched to or from sertraline. Conclusion: Implementing the sertraline tablet-splitting program significantly decreased the PMPM cost of sertraline prescriptions, but it did not significantly decrease total costs of sertraline, nor did it result in disproportionate numbers of patients switching from sertraline to other SSRIs. Total costs and PMPM costs of the other four SSRI drugs did not decrease.

Original languageEnglish (US)
Pages (from-to)497-502
Number of pages6
JournalJournal of the American Pharmacists Association
Volume43
Issue number4
DOIs
StatePublished - Jan 1 2003

    Fingerprint

Keywords

  • Citalopram
  • Drug costs
  • Fluoxetine
  • Fluvoxamine
  • Insurance claim review
  • Paroxetine
  • Pharmaceutical economics
  • Prescription fees
  • Retrospective studies
  • Sertraline

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Pharmacy
  • Pharmacology

Cite this